Russia's Sputnik V vaccine against Covid-19 will cost governments much lower than that of Pizer's and Moderna's, the official Twitter handle of the world's first registered vaccine against the pandemic said on Sunday.
Pfizer said Friday it is asking U.S. regulators to allow emergency use of its COVID-19 vaccine, starting the clock on a process that could bring limited first shots as early as next month and eventually an end to the pandemic -- but not until after a long, hard winter.
Global drugmakers Pfizer and BioNTech on Wednesday said that their coronavirus vaccine was found 95 per cent effective in the final analysis of the Phase 3 trial, making way for the companies to secure emergency authorisation from US regulators. Chances are that the vaccine deliveries could start before Christmas.
The Phase 3 study of our COVID-19 vaccine candidate has met all primary efficacy endpoints. The study reached 170 confirmed cases of COVID19, with the vaccine candidate BNT162b2 demonstrating 95% efficacy beginning 28 days after the first dose.
The cold-chain requirement for the anti-coronavirus vaccine candidate developed by Pfizer at a temperature of minus 70 degrees Celsius poses a big challenge, but the government is examining the possibilities if at all the vaccine has to be obtained by India, it said on Tuesday.
The US is planning to start vaccinating the "most vulnerable" from next month if Pfizer's coronavirus vaccine candidate is quickly approved by the drug regulators, US Health Secretary Alex Azar has said.
Delhi AIIMS director on Wednesday said Pfizer's potential coronavirus vaccine has to be kept at minus 70 degrees Celsius, which will be a challenge for developing countries like India.
US pharmaceutical giant Pfizer and German biotech firm BioNTech said their coronavirus vaccine was more than 90 per cent effective in preventing COVID-19 among those without evidence of prior infection.
Albert Bourla, the head of pharmaceutical giant Pfizer, which is among the companies developing a coronavirus vaccine, said that there is a "good chance" the company will know whether its vaccine works by the end of October.
Pfizer Inc. Chief Executive Officer Albert Bourla said the Americans are "likely" to get a shot of the COVID-19 vaccine by year-end. He expected the vaccine to be deployed before the public in the U.S. before the end of 2020.
Pfizer and BioNTech said the Covid-19 vaccine they are jointly developing is on track to be submitted for regulatory review as early as October, as they released additional data from an early-stage study.
According to the study the vaccine candidate is delivered intramuscularly, and enables human cells to produce proteins part of the SARS-CoV-2 receptor-binding domain, against which the immune system is trained to produce antibodies.
Moderna and Pfizer (which has partnered with German biotech firm BioNTech to develop a COVID-19 vaccine) have announced that they will be including a limited number of HIV-positive volunteers in the final stage of trials.
US-based Pfizer and German biotech firm BioNTech have announced the start of a late stage clinical trial of a Covid-19 vaccine jointly developed by the two companies. The Phase 2/3 study will involve up to 30,000 participants between 18 and 85 years of age.
The US government has agreed to pay $1.95 billion for 100 million doses of a potential Covid-19 vaccine jointly developed by Pfizer and BioNTech, the two companies said on Wednesday.
Two experimental COVID-19 vaccine jointly developed by German Biotech firm BioNTech and US pharmaceutical gaint Pfizer have received "fast track" designation from the US drug regulator FDA. The candidates, BNT162b1 and BNT162b2, are the most advanced of the at least four vaccines being assessed by the companies.
The government on Monday sought vacation of Delhi High Court's interim order staying the ban on some fixed dose combinations (FDC) medicines, saying it would be "against public interest and patient safety"
The Delhi High Court today granted US-based pharmaceutical major Pfizer a stay on the government ban on its popular codeine-based cough syrup Corex. The ban was part of a larger notice by the government prohibiting sale, manufacture and distribution
New York: In one of the biggest business deals, Global pharma major Pfizer Inc and Botox maker Allergan Plc have entered into a merger agreement for a total enterprise value of about USD 160 billion.The
London: US drugs giant Pfizer announced it has made a final improved bid for British competitor AstraZeneca, valuing the company at 69 billion (USD 117 billion).The offer of Rs.55 a share is 15 per cent
Top News
Latest News
